Orphenadrine hydrochloride

305.84

305.15500

206-435-4

82357

2811

DTXSID5025815

N - Nervous system

2922199090

12.47000

4.46460

Orphenadrine hydrochloride appears as odorless white or almost white crystalline powder. pH (aqueous solution) about 5.5. Bitter numbing taste. (NTP, 1992)

0.295 g/cm³

156-157 °C

-195 °C

107.1ºC

>45.9 [ug/mL]

2-8°C

LD50 oral in rat: 255mg/kg

May be sensitive to prolonged exposure to light and air. Water soluble.

Amines, Phosphines, and Pyridines

ORPHENADRINE HYDROCHLORIDE is incompatible with strong oxidizers. (NTP, 1992)

III

6.1(b)

3249

3

22

36

KR6300000

Xn

Stable. Incompatible with strong oxidizing agents.

Missing Phrase - N15.00950417

H301

Flash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)

Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)

Excerpt from ERG Guide 154 [Substances - Toxic and/or Corrosive (Non-Combustible)]: As an immediate precautionary measure, isolate spill or leak area in all directions for at least 50 meters (150 feet) for liquids and at least 25 meters (75 feet) for solids. SPILL: Increase, in the downwind direction, as necessary, the isolation distance shown above. FIRE: If tank, rail car or tank truck is involved in a fire, ISOLATE for 800 meters (1/2 mile) in all directions; also, consider initial evacuation for 800 meters (1/2 mile) in all directions. (ERG, 2016)

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned. STORAGE PRECAUTIONS: You should protect this chemical from exposure to light. Keep the container tightly closed under an inert atmosphere, and store under refrigerated temperatures. (NTP, 1992)

RECOMMENDED RESPIRATOR: Where the neat test chemical is stored, weighed and diluted, wear an approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)|Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)|Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)|A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)|Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2B6. (See all compounds classified as Cytochrome P-450 CYP2B6 Inhibitors.)

SYMPTOMS: Symptoms of exposure to this compound include dryness of mouth, loss of accommodation, dilated pupils, photophobia, increased intraocular pressures, difficulty in swallowing, thirst, flushing and dryness of the skin, transient bradycardia followed by tachycardia with palpitations and arrhythmias, urinary retention, reduction in the tone and motility of the gastrointestinal tract leading to constipation, vomiting, giddiness, staggering, retrosternal pain due to increased gastric reflux, rapid or stertorous respiration, hyperpyrexia restlessness, confusion, excitement, hallucinations, delirium and rash on the face and upper trunk. Severe exposure may cause central nervous system depression with hypertension or with circulatory failure and respiratory depression. There have been cases of dizziness, involuntary jerky movements of the limbs, nervous movements and burning sensation in the throat. Other symptoms of exposure include blurred vision, cyanosis, mydriasis with absent light reflex, coma, clonic convulsions, respiratory arrest and alarming disturbances in cardiac mechanisms. In young children, exposure can cause severe intoxication and death. Glaucoma and widely dilated unreactive pupils have been reported. Symptoms of exposure to this type of compound include lethargy, drowsiness, fatigue, hypnosis, vertigo, ataxia, tinnitus, central nervous system hyperexcitability, sedation, tremors, anxiety, insomnia, toxic psychoses, gastrointestinal disturbances, anorexia, nausea, abdominal distress, diarrhea and pulmonary edema. Other symptoms of exposure to this type of compound include headache, nervousness, disorientation, stupor, hyperreflexia, nystagmus and hyperthermia. ACUTE/CHRONIC HAZARDS: This compound is harmful by ingestion and inhalation. It may cause irritation. When heated to decomposition it emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and hydrogen chloride gas. (NTP, 1992)

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop. SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment. INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing. INGESTION: If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital. (NTP, 1992)

Citrate, Norflex Orphenadrine

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients